New Webinar Learning Opportunity! The Future of Injectable PrEP
via Zoom
Register HERE
About the speaker:
Dr. Albert Liu, MD, MPH is the Clinical Research Director of Bridge HIV and a Clinical Professor of Medicine at UCSF. As a leader in HIV prevention research, he conducts clinical trials of novel PrEP agents and evaluates implementation strategies to support equitable PrEP scale-up in real-world settings. He also serves as PrEP Committee co-chair of the SF Getting to Zero Consortiums and is an attending physician at Zuckerberg SF General Hospital.
Overview:
Injectable PrEP formulations are a promising intervention for increasing PrEP effectiveness and reducing disparities in HIV transmission, particularly among communities of color, youth, cis-women, transgender and gender diverse communities. In this webinar, Dr. Al Liu will provide updates on the latest clinical data for lenacapavir injectable PrEP medication, and along with Whitman-Walker Health colleagues, discuss overcoming barriers to implementation for clinicians, health departments and CBOs.
Learning Objectives:
- Discuss recent clinical data demonstrating superiority of the injectable HIV prevention medication lenacapavir to oral medications.
- List two ways that injectable PrEP formulations can contribute to combating disparities in HIV prevention.
- Describe three individual and organizational barriers to dissemination of injectable PrEP and how they may be addressed.
